A combination regimen of bortezomib, cyclophosphamide and betamethasone gives quicker, better and more durable response than VAD/CyBet regimens: results …

K Uttervall, J Admasie, E Alici, J Lund, J Liwing… - Acta …, 2013 - karger.com
Background: Induction therapy for multiple myeloma (MM) and remission status before high-
dose treatment (HDT) have been shown to be prognostic factors for survival outcome …
被引用次数：6 相关文章

A Combination Regimen of Bortezomib, Cyclophosphamide and Betamethasone Gives Quicker, Better and More Durable Response than VAD/CyBet Regimens …

K Uttervall, J Lund, J Liwing, M Barendse… - Acta …, 2013 - search.ebscohost.com
Background: Induction therapy for multiple myeloma (MM) and remission status before high-
dose treatment (HDT) have been shown to be prognostic factors for survival outcome …

A Combination Regimen of Bortezomib, Cyclophosphamide and Betamethasone Gives Quicker, Better and More Durable Response than VAD/CyBet Regimens …

K Uttervall, J Admasie, E Alici, J Lund, J Liwing… - Acta …, 2013 - karger.com
Background: Induction therapy for multiple myeloma (MM) and remission status before high-
dose treatment (HDT) have been shown to be prognostic factors for survival outcome …

A combination regimen of bortezomib, cyclophosphamide and betamethasone gives quicker, better and more durable response than VAD/CyBet regimens: results …

K Uttervall, J Admasie, E Alici, J Lund… - Acta …, 2013 - pubmed.ncbi.nlm.nih.gov
Background Induction therapy for multiple myeloma (MM) and remission status before high-
dose treatment (HDT) have been shown to be prognostic factors for survival outcome …

A combination regimen of bortezomib, cyclophosphamide and betamethasone gives quicker, better and more durable response than VAD/CyBet regimens: results …

K Uttervall, J Admasie, E Alici, J Lund, J Liwing… - Acta …, 2013 - europepmc.org
Background Induction therapy for multiple myeloma (MM) and remission status before high-
dose treatment (HDT) have been shown to be prognostic factors for survival outcome …
[PDF] archive.org

[PDF][PDF] A Combination Regimen of Bortezomib, Cyclophosphamide and Betamethasone Gives Quicker, Better and More Durable Response than VAD/CyBet Regimens …

K Uttervall, J Admasie, E Alici, J Lund, J Liwing… - Acta …, 2013 - scholar.archive.org
Background: Induction therapy for multiple myeloma (MM) and remission status before high-
dose treatment (HDT) have been shown to be prognostic factors for survival outcome …

A Combination Regimen of Bortezomib, Cyclophosphamide and Betamethasone Gives Quicker, Better and More Durable Response than VAD/CyBet Regimens …

K Uttervall, J Admasie, E Alici, J Lund, J Liwing… - Acta …, 2013 - diva-portal.org
Background: Induction therapy for multiple myeloma (MM) and remission status before high-
dose treatment (HDT) have been shown to be prognostic factors for survival outcome …